<DOC>
	<DOCNO>NCT01302587</DOCNO>
	<brief_summary>This study evaluate effectiveness dose counter inhaler device use deliver medication people diagnose asthma COPD .</brief_summary>
	<brief_title>A Study Evaluate Integrated Dose Counter Albuterol Hydrofluoroalkane ( HFA ) Metered Dose Inhaler ( MDI )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Written inform consent/assent General good health Asthma COPD Capable understanding requirement , risk , benefit study participation . Able demonstrate proper metereddose inhaler use technique . Other inclusion criterion apply History lifethreatening asthma COPD define protocol asthma COPD episode require intubation and/or associate hypercapnia , respiratory arrest hypoxic seizure . Culturedocumented suspected bacterial viral infection upper low respiratory tract , sinus , middle ear resolve within 2 week Screening Visit . Is treated longacting Î²2agonist alone . Is currently treat Ventolin HFA . Any asthma COPD exacerbation require oral corticosteroid within 2 month Screening Visit . A subject must hospitalization asthma COPD within 4 month prior Screening Visit . Historical current evidence clinically significant nonasthmatic acute chronic condition . Uncontrolled hypertension History adverse reaction component HFAMDI formulation . Participation investigational drug study within 30 day precede Screening Visit . Other exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>